Headshot of Israel Gasperin

Israel Gasperin
Engineering Scientist, Founder & CEO
Zentrela, Inc.
POSTER PRESENTER
SCIENCE

Objective and Neurophysiological (EEG) Evidence of multiple cannabinoid benefits

Assuming Product A refers to the CBG trial, this preliminary EEG analysis provides objective, neurophysiological, and statistically supported evidence that the investigational product may help individuals better manage stress and anxiety.

These findings offer valuable insights for clinicians and researchers interested in further exploring its potential therapeutic applications in conditions such as PTSD and other anxiety disorders.

Assuming Product A refers to the CBG trial, this EEG analysis provides objective, neurophysiological, and statistically supported evidence that the investigational product may help individuals better manage stress and anxiety. These findings
offer valuable insights for clinicians and researchers seeking to further explore its potential therapeutic applications in conditions such as PTSD and other anxiety disorders.

Anxiety is only one of the EEG-based mental states analyzed in our research. We will also present results from this and other ongoing trials examining additional cannabis-related effects and their interrelationships, including:

● THC-induced psychoactive levels
● Anxiety
● Sadness
● Anger
● Mood
● Pain perception

Learning Objectives:

  • Demonstrate objective, EEG-based differentiation of cannabinoid effects like CBG, THCV, CBD, THC

  • Reveal new insights beyond subjective self-reports

  • Establish a scientific foundation for evidence-based product development

BIO
Israel Gasperin is the Founder and CEO of Zentrela Inc., a Canadian neurotechnology company pioneering the use of AI-powered EEG analysis to objectively measure the psychoactive and wellness effects of cannabinoids and other active ingredients in consumer products. An Engineering Scientist by training and a graduate of McMaster University, Israel founded Zentrela in 2016 to fulfill a clear mission: to democratize brainwave analysis and set new scientific standards for product-effect research across the cannabis, nutraceutical, and wellness industries. Under his leadership, Zentrela developed the Cognalyzer®, the world’s first standardized EEG platform capable of quantifying non-therapeutic mental states such as relaxation, energy, focus, stress, anxiety, sadness, and pain perception with statistical rigor and regulatory compliance. Through this innovation, Zentrela has become a trusted research partner for licensed producers, research hospitals, and universities across North America and Europe. Israel and his team have executed more than 30 IRB- and Health Canada-approved human trials, building the world’s largest EEG dataset of consumer cannabis and cannabinoid experiences. This growing data bank supports the training of proprietary machine-learning models that can objectively quantify product effects in a fast, cost-effective, and scientifically validated manner, providing evidence far beyond the limitations of self-reported questionnaires.


Zentrela’s collaborations include leading researchers such as Dr. Carrie Cuttler (Washington State University, Department of Psychology) on the EEG-based assessment of CBG’s relaxation and anxiety-management potential, and Dr. François-Olivier Hébert (Research Hospital of Montreal – CHUM, Department of Psychiatry) on studies analyzing the psychoactive, anxiolytic, and mood-modulating effects of THC and CBD. Israel is an advocate for evidence-based cannabis innovation, emphasizing that objective, physiological data are key to bridging the gap between scientific discovery, product differentiation, and consumer trust. He frequently speaks about the importance of transitioning from anecdotal and subjective claims toward quantifiable neuroscience-driven evidence that can accelerate both medical and non-medical cannabis research. Through Zentrela’s growing network of research sites in Canada and the USA, Israel continues to push the boundaries of applied neuroscience and AI. His vision is to make objective brainwave analysis the global standard for evaluating how cannabis and other active compounds influence the human mind, ensuring that the next generation of wellness and therapeutic products are built on trustworthy, physiological, and scientifically validated evidence.

View CannMed Resources Below:

Featured image for “Using EEG to Measure Psychoactive Potency of Cannabis Products with Israel Gasperin”
Mar. 19, 2025

Using EEG to Measure Psychoactive Potency of Cannabis Products with Israel Gasperin

Image